Nektar divests manufacturing site and reagent arm for $90M

Anna Brown

News Reporter

Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nektar divests manufacturing site and reagent arm for $90M

Anna Brown

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Nek­tar di­vests man­u­fac­tur­ing site and reagent arm for $90M

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Nektar divests manufacturing site and reagent arm for $90M